AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

Similar documents
Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers

NURSING INTAKE. Provider Name: Provider Signature: Nursing Summary. Are you pregnant at this time?

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

TELEPHONE SCREENING DEMOGRAPHIC INFO

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Does ultram show up as an opiate

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Vivitrol Drug Court and Medication Assisted Treatment

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

Disclosures. Get Your Specimens in Order:

Buprenorphine & Controlled Substance Treatment Agreement

PITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018

Effective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use

SUBSTANCE ABUSE PATIENT

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Patient Agreement for the use of Opioid Medications

Quest Diagnostics Drug Testing Index Full Year 2015 Tables

Triage, Assessment and Treatment Planning

NIDA Quick Screen V1.0F1

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

Addiction History. Patient Assessment. Objectives. Cost. Initial Screen. Patient Assessment 25/04/2017. Substances. Age Started

Buprenorphine treatment

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

Medication-Assisted Treatment. What Is It and Why Do We Use It?

2. Is this request for a preferred medication? Y N

Testing for Controlled Substances

Treating Opioid Addiction

D. Janene Holladay, M.D. Board Certifications: American Board of Anesthesiology American Board of Pain Medicine American Board of Addiction Medicine

Chronic Pain, Opioids, & Addiction: Assessing and Managing Risk

Oregon ACEP Opioid Prescribing Guidelines. Why are we talking about this?

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures

Conflict of Interest Disclosure

Medication Assisted Treatment

Objectives. Patient Assessment Methadone and Suboxone Addiction History. Patient Assessment. Initial Screen. Cost 14/04/2016

Medication Assisted Treatment. Nicole Gastala, MD

Vermont Hub and Spoke Model Treatment Need Questionnaire

If you do not have health insurance, the initial appointment will be $232. Follow-up appointments will be $104.

Medication Assisted Treatment: Setting Up, Operating, Integrating into Primary Care. Ako Jacintho, MD Director of Addiction Medicine HealthRIGHT 360

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCE Narrative

Powering Efficient Behavioral Health Care Services

Dr Alistair Dunn. Lead Clinician Northland Health Community Mental Health & Addictions Northland DHB Whangarei

Prescription Drug Impact in the Workplace

Opioid Dependence and Buprenorphine Management

SUBOXONE FILM NEW PATIENT INTRODUCTION

Methadone Maintenance 101

POLICIES AND PROCEDURES. Lead Department/Committee: (Refer also to GFHS Narcotic Treatment Protocols) Statement of Need

Medication Assisted Treatment in an Ideal Micro-Practice. Case: Typical Opioid Dependent Patient. John Machata, MD Wickford Family Medicine

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

The Emergence of Gabapentin as a Drug of Abuse in a Cohort of Rural Appalachian Drug Users

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

Prescription Opioids

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

Outlook and Outcomes Fiscal Year 2011

Prescription Monitoring Program. One Agency s Experience. Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA

Patient Initiation: Buprenorphine/Naloxone

Washington State s Overdose Epidemic

Policy and Issuance Patient Age Group: ( ) N/A ( ) All Ages ( ) Newborns ( X) Pediatric ( X) Adult

Drug & Alcohol Testing in. Canada. Point of Care Testing

Controlled Substance Monitoring in the Age of the Opioid Epidemic

Session 7: Opioids and Club Drugs 7-1

Prescription Drug Monitor Programs (PMDP): Combating prescription drug misuse and abuse. A physician s perspective.

Treatment Approaches for Drug Addiction

BENZODIAZEPINE DEPENDENCE AMONG MULTIDRUG USERS IN THE CLUB SCENE. Steven P. Kurtz and Mance E. Buttram

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

problems/medications: Current supplements/vitamins/herbs: Past medical problems/medications: Other doctors/clinics seen regularly:

Youth, Opioid Use and Treatment Options. CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016

DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide.

Prescription Opioid Addiction

NIDA-Modified ASSIST Prescreen V1.0 1

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Medication-Assisted Treatment (MAT) Overview

John Murphy DO, MS Lynx Healthcare

Treating Opioid Use Disorders: An Update for Counselors and Other Providers

the facts about BUPRENORPHINE for Treatment of Opioid Addiction

DrugConfirm Advanced Urine Dip Cards.

Chronic Pain Management in the Primary Care Setting

Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

Screener and Opioid Assessment for Patients with Pain- Revised (SOAPP -R)

MEDICAL POLICY Drug Testing

Annual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use

Opioid Pain Contracts: A Resident Driven Quality Improvement Project

MEDICAL POLICY No R2 DRUG TESTING

Recent Developments in FRA s Post-Accident Toxicological Testing Program

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Benzodiazepine Misuse Abuse - Dependence Using for recreational purposes Continued long term use against medical advise Use of drug with other potenti

Barriers To Recovery For Bangor's Buprenorphine Patients

Recommendations in Opioid Prescribing Guidelines for Chronic Pain

SECTION 2: CURRENT CONCERNS Briefly describe the current concerns you would like to discuss with your counselor:

2/7/2017. Avoid compassion traps. Avoid All or Nothing Traps. Some Explanatory Models of Addiction

Talking with your doctor

Transcription:

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic phases of the treatment opioid use disorders using buprenorphine/naloxone Try to alleviate your anxiety Discuss ways to integrate buprenorphine/naloxone treatment into a primary care setting Review patient logs and DEA requirements Disclosures NONE 1

Opioid Use Disorder is a problem 2

Focus on Buprenorphine/Naloxone 3

Phases of Buprenorphine/Naloxone Treatment Pretreatment Screening Intake Induction Stabilization Maintenance Medically Supervised Withdrawal Meet Jane Jane is a 26 yo female who calls your office to discuss treating her heroin use. She found your office information on the web. Initial Patient Contact Pretreatment screening Many patients will call for information on bup/nx. Pretreatment screening is used to determine whether office-based treatment is the best option for the patient. Do you want someone in the clinic to do an initial screen of these patients? Who should perform the pretreatment screening? Trained office staff Behavioral health specialist Provider 4

Intake for evaluation Intake Primary goal is to establish a medical record for the patient s suitability for office-based treatment for opioid dependence. Should be done by trained medical staff Behavioral Health providers Residents Mid-levels Attendings Initial patient contact It is common for the pretreatment screening and intake to be done at one office visit Some offices have a contact person in the office who can perform the pretreatment screening by phone. May be any staff member who is trained to appropriately screen for opioid dependence and discuss whether the patient needs more intensive treatment than your office can offer. Screening for office based treatment Assess for degree of opioid dependence Drug Abuse Screening Test (DAST-10) CAGE- AID TWEAK questionnaire Assess for readiness for treatment Assess coverage for prescription medication Bup/Nx is fairly expensive for self pay patients Bup/Nx may need Prior Authorization Past treatment attempts If many prior attempts, may need a higher level of care Desire to get care 5

Welcome Jane Chief complaint I want to get that prescription to get off drugs Intake details Full history is important Document the patient s need for office-based treatment of opioid dependence Document a diagnosis of opioid dependence Assess for any untreated psychiatric conditions that might interfere with treatment Documenting Opioid Dependence DSM-V criteria Substance Dependence Assessment form Clear documentation using above criteria documented in the progress note 6

Intake Thorough medical history, family history and social history should be done Drug abuse history When began using drugs What drugs have been used What is the route of administration Smoking, snorting, IVDU Past treatment history Legal or other problems related to drug use Intake Urine drug screen should be done to confirm current opioid use Urine drug screen should also be used to screen for polydrug abuse and other medications that may interfere with treatment Remember the drug screen is not meant to be punitive 7

Point of Care Testing Cocaine Opiates Methamphetamines THC Amphetamines PCP Benzodiazepines Barbiturates Methadone Oxycodone Send out to Lab UDM Amphetamines Barbiturates Benzodiazepines Cocaine Methadone Marijuana Opiates Propoxyphene UDM Pain Amphetamines Barbiturates Benzodiazepines Cocaine Demerol Fentanyl Methadone Opiates Oxycodone PCP Propoxyphene Soma THC Tramadol Tricyclics Zolpidem Length of time specific drugs are detected in urine Drug Time of detection Alcohol 7 12 hours Amphetamines 48 hours Barbiturates Short: 24-48 hours, Long: up to 3 weeks Benzodiazepines Cocaine Marijuana Methamphetamines MDMA Opioids PCP Short: 3 days, Long: up to 30 days 2 4 days 3 30 days 3 5 days 48 hours Depends on drug/metabolite 8 days 8

Intake Bloodwork is recommended prior to starting Bup/Nx treatment Ascertain other medical conditions Anemia, HIV, Hepatitis C Establish baseline liver function Physical exam is recommended Jane s story Began using pain pills as a teenager. Used at parties, but then started using more frequently She transitioned to smoking heroin with her friends at the age of 18 because it was cheaper. Soon she was using daily She started using IV at the age of 23. She says she has used daily since that time She uses about two bags daily She gets sick if she doesn t use after about 8 hours She has never sought treatment before but tried bup/nx from a friend when she couldn t get heroin More history PMH: otherwise negative Psychiatric Hx: she endorses anxiety and depression but does not have a formal psychiatric diagnosis PSH: no surgeries, but has had I&D of several abscess in the ED FH: negative Soc Hx: lives in town with her boyfriend, she works parttime as a cashier. + tobacco use daily, 1ppd. No alcohol use. She has used cocaine and methamphetamine in the past, but not regularly. Daily heroin use Labs: normal, negative HIV, HCV 9

Next step The patient meets criteria for office-based treatment for opioid dependence You determine to begin the treatment Initiate treatment agreement Initial Rx How many doses Minimal quantity is recommended on first Rx Most Medicaid, Medicare and insurance coverage will allow 14 day supply without prior authorization Treatment Agreement It is required that you have a treatment contract for the patients on buprenorphine Similar to a controlled substance contract May want to include clause about Counseling Avoiding potentially harmful substances (benzos, alcohol, sedatives) pregnancy Induction Office-based induction Recommended Not always feasible Good for patients who have never tried Bup/Nx Patient needs to be instructed to arrive in mildmoderate withdrawal Home induction Becoming more popular in practice Easier for patients Easier for the providers with very busy schedules Patient needs to be given clear dosing instructions and a contact number for any problems, questions or concerns Close office or phone contact recommended 10

Induction dosing Assess for adequate withdrawal Start with 4mg dose Leave until completely dissolved then spit or swallow the saliva Monitor for worsening symptoms of withdrawal May dose an additional half tablet if symptoms persist Maximum dose for first 24 hours is 16mg buprenorphine/naloxone Some patients may need 20mg for comfort of severe symptoms Day 2- begin with full dose from prior day 11

Jane is determined a good candidate After discussion, Jane wants to try office based treatment You determine she can probably do a home induction because she has tried Bup/Nx on the streets before You give her a 7 day supply of medication and home dosing instructions Stabilization Induction is completed when the patient experiences no withdrawal symptoms Stabilization is the fine-tuning of the Bup/Nx dose Goal is to find the minimum dose necessary to hold the patient in treatment, suppress opioid withdrawal and suppress other opioid use Stabilization Most patients stabilize on 16mg buprenorphine per day (range 4mg to 24mg) Dose adjustments should occur every 3 to 7 days to allow for steady-state levels 12

Jane comes in for follow up Overall feeling well Has found that 16mg is keeping her withdrawal symptoms under control She is still struggling with cravings but did not use What can you do with this? Increase her dose of medication Utilize counseling Explore triggers Stabilization Very fragile time for the patients Great time to begin psychosocial counseling Individual counseling Group therapy NA or AA SMART recovery Here to Help Counseling Thoughts for your clinic Who can you refer to for counseling? How will you verify the patient has attended? Trust the patient Signature sheet Verify appointments attended in your system Do you need a release of information to discuss the patient s care with the counselor? 13

Maintenance Prevent opioid withdrawal symptoms Suppress opioid cravings Prevent use of self-administered opioids Duration of the maintenance phase depends on the individual needs of the patient May be weeks to years Continue regular office visits Frequency may decrease with time Medically supervised withdrawal Not recommended in most patients Some patients will progress from stabilization to medically supervised withdrawal The Bup/Nx dose should be slowly tapered at a rate that both physician and patient consider acceptable Patients should be prepared fro mild, transitory withdrawal symptoms Fatigue, anorexia, irritability, insomnia, anxiety DEA requirements Any provider who prescribes buprenorphine must apply for a wavier per DATA 2000. Usually part of your training You will receive an X number that must be written on all buprenorphine prescriptions Documentation of opioid dependence must be in the medical record 14

DEA requirements Records on buprenorphine May need to be kept separate from primary care records If not, then a consent for the buprenorphine records to be part of the medical record should be obtained. May be part of the consent for treatment or buprenorphine contract DEA requirements A log of active Bup/Nx patients must be upkept Patient identifier Date of prescription Number of tablets prescribed Spreadsheet, paper, card file, EHR patient list The attending X number will be the legal prescription writer. Residents should keep a log of their patients, but each attending will need the log of patients at all times DEA Audits The DEA may come to the clinic for an audit Unannounced visit Will ask to see log of active patients Will review charts of active patients to assure proper prescribing of buprenorphine 15

How to get trained! Questions or Comments? 16